Optimizing Neoadjuvant Chemotherapy for Initially Resectable Colorectal Cancer Liver Metastasis

Neoadjuvant chemotherapy for initially resectable colorectal cancer liver metastasis aims at tumor downsizing, evaluating biological behavior, and reducing postoperative recurrence risk. Balancing tumor reduction benefits with hepatic injury risks and the need for timely surgery is crucial. Precision medicine’s role in tailoring neoadjuvant regimens, such as gene testing, and a multidisciplinary approach are emphasized. Tailored management post-chemotherapy is necessary due to diverse biological behaviors. Overall, this review underscores the importance of refining neoadjuvant strategies for improved patient outcomes.